Dose-ranging Study of Once-daily Regimen of BAY 59-7939 in the Prevention of VTE in Patients Undergoing Elective Total Hip Replacement

NCT00396786 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

877

Enrollment

INDUSTRY

Sponsor class

Conditions

Venous Thromboembolism

Interventions

DRUG: Rivaroxaban (Xarelto, BAY59-7939)
DRUG: Rivaroxaban (Xarelto, BAY59-7939)
DRUG: Rivaroxaban (Xarelto, BAY59-7939)
DRUG: Rivaroxaban (Xarelto, BAY59-7939)
DRUG: Rivaroxaban (Xarelto, BAY59-7939)
DRUG: Enoxaparin

Sponsor

Bayer